Winton Group’s Arbutus Biopharma ABUS Stock Holding History

Winton Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-42,373	Closed	-$118K	–	1378
2019 Q4	$118K	Sell	42,373 -39,555	-48%	-$64K	﹤0.01%	1479
2019 Q3	$125K	Buy	+81,928	New	+$141K	﹤0.01%	1444

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Winton Group's ABUS Position: Q1 2020 in Review

Winton Group sold out of Arbutus Biopharma (ABUS) in Q1 2020, closing a stake of 42,373 shares — an estimated $118K sold.

Winton Group first reported a position in ABUS in Q3 2019 and held it in 2 quarters. The position peaked at $125K in Q3 2019. 48 funds tracked by Wall St. Rank hold ABUS as of Q1 2020.

Winton Group reported no remaining Arbutus Biopharma position as of Q1 2020 after selling out during the quarter.
Winton Group sold 42,373 Arbutus Biopharma shares in Q1 2020, an estimated $118K.
Winton Group first reported a position in Arbutus Biopharma in Q3 2019 and held it in 2 quarters.
Winton Group's Arbutus Biopharma position peaked at $125K in Q3 2019.
48 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2020.

Based on Winton Group's 13F filing for Q1 2020, filed 11 May 2020.